Bristol Myers Squibb Psoriatic Arthritis Clinical Trials – Currently Enrolling

29 September 2022


These Psoriatic Arthritis (PsA) studies are seeking to determine if the investigational medication deucravacitinib is safe and effective in reducing the symptoms of PsA. These studies are evaluating if deucravacitinib may potentially correct the overactive immune response that causes inflammation in people with PsA.

If eligible, study participants may receive:

  • Study-related medical care
  • Study-related lab work and procedures
  • No charge for the investigational medication, study doctor visits, laboratory work, tests, or procedures that are needed for the study. Study staff can provide additional details regarding any type of reimbursement for this study.